High versus low concentration botulinum toxin A for benign essential blepharospasm: Does dilution make a difference?

Ophthalmic Plastic and Reconstructive Surgery

Volumn 25, Issue 2, 2009, Pages 81-84

  Boyle, Michael H ^a,c   McGwin Jr , Gerald ^a,b   Flanagan, Courtney E ^a   Vicinanzo, Matthew G ^a   Long, John A ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT;

ADULT; AGED; ARTICLE; BLEPHAROSPASM; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIPLOPIA; DRUG DOSE COMPARISON; DRY EYE; EPIPHORA; FEMALE; HEMATOMA; HUMAN; HYPEREMIA; MALE; PAIN; PRIORITY JOURNAL; PTOSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; CONTUSION; DOSE RESPONSE; ERYTHEMA; HOSPITALIZATION; INJECTION; MIDDLE AGED; OSMOLARITY; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; BLEPHAROSPASM; BOTULINUM TOXIN TYPE A; CONTUSIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHEMA; FEMALE; HUMANS; INJECTIONS; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; OSMOLAR CONCENTRATION; PAIN; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 67049160149     PISSN: 07409303     EISSN: None     Source Type: Journal    
DOI: 10.1097/IOP.0b013e31819946c4     Document Type: Article

References (25)

1. Hall TA, McGwin G, Searcey K, et al. Health-related quality of life and psychosocial characteristics of patients with benign essential blepharospasm. Arch Ophthalmol 2006;124:116-119 (Pubitemid 43063898)
2. Engstrom PF. Effectiveness of botulinum toxin therapy for essential blepharospasm. Ophthalmology 1987;94:971-975 (Pubitemid 17144497)
3. Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. J Pediatr Ophthalmol Strabismus 1980;17:21-25 (Pubitemid 10174336)
4. Frueh BR, Felt DP, Wojno TH, Musch DC. Treatment of blepharospasm with botulinum toxin. A preliminary report. Arch Ophthalmol 1984;102:1464-1468 (Pubitemid 14048632)
5. Hankins CL, Strimling R, Rogers GS. Botulinum A toxin for glabellar wrinkles. Dose and response. Dermatol Surg 1998;24: 1181-1183 (Pubitemid 28533284)
6. Hsu TS, Dover JS, Arndt KA. Effect of volume and concentration on the diffusion of botulinum exotoxin A. Arch Dermatol 2004; 140:1351-1354
7. Carruthers A, Carruthers J, Cohen J. Dilution volume of botulinum toxin type A for the treatment of glabellar rhytides: does it matter? Dermatol Surg 2007;33(1 Spec No.):S97-S104. (Pubitemid 46051407)
8. Carruthers A, Bogle M, Carruthers JD, et al. A randomized, evaluator-blinded, two-center study of the safety and effect of volume on the diffusion and efficacy of botulinum toxin type A in the treatment of lateral orbital rhytides. Dermatol Surg 2007;33: 567-571 (Pubitemid 46650366)
9. Snir M, Weinberger D, Bourla D, et al. Quantitative changes in botulinum toxin a treatment over time in patients with essential blepharospasm and idiopathic hemifacial spasm. Am J Ophthalmol 2003;136:99-105. (Pubitemid 36794501)
10. Poonyathalang A, Preechawat P, Jamnansiri U. Low-dose botulinum toxin a for treatment of blepharospasm and hemifacial spasm. Jpn J Ophthalmol 2005;49:327-328 (Pubitemid 41264812)
11. Pang AL, O'Day J. Use of high-dose botulinum A toxin in benign essential blepharospasm: is too high too much? Clin Experiment Ophthalmol 2006;34:441-444 (Pubitemid 44027231)
12. Levy RL, Berman D, Parikh M, Miller NR. Supramaximal doses of botulinum toxin for refractory blepharospasm. Ophthalmology 2006;113:1665-1668 (Pubitemid 44292313)
13. BOTOX® [Package insert] Irvine, Calif., U.S.A.: Allergan, Inc, 2006.
14. Garcia A, Fulton E. Cosmetic denervation of muscles of facial expression with botulinum toxin. Dermatol Surg 1996;22:39-43.
15. Flynn TC, Carruthers A, Carruthers J. Surgical pearl: the use of the Ultra-Fine II short needle 0.3-cc insulin syringe for botulinum toxin injections. J Am Acad Dermatol 2002;46:931-933
16. Rosner B, Glynn RJ, Lee MT. Incorporation of clustering effects for the Wilcoxon rank sum test: a large sample approach. Biometrics 2003;59:1089-1098 (Pubitemid 38021239)
17. Rosner B, Glynn RJ, Lee MT. The Wilcoxon signed rank test for paired comparisons of clustered data. Biometrics 2006;62:185-192
18. Rosner B, Glynn RJ, Lee MT. Extension of the rank sum test for clustered data: two-group comparisons with group membership defined at the subunit level. Biometrics 2006;62:1251-1259
19. Klein AW. Dilution and storage of botulinum toxin. Dermatol Surg 1998;24:1179-1180
20. Kim HS, Hwang JH, Jeong ST, et al. Effect of muscle activity and botulinum toxin dilution volume on muscle paralysis. Dev Med Child Neurol 2003;45:200-206
21. Shaari CM, Sanders I. Quantifying how location and dose of botulinum toxin injections affect muscle paralysis. Muscle Nerve 1993;16:964-969 (Pubitemid 23246323)
22. Francisco GE, Boake C, Vaughn. A. Botulinum toxin in upper limb spasticity after acquired brain injury: a randomized trial comparing dilution techniques. Am J Phys Med Rehabil 2002;81:355-363 (Pubitemid 34412072)
23. Söylev MF, Koçak N, Kuvaki B, et al. Anesthesia with EMLA cream for botulinum A toxin injection into eyelids. Ophthalmologica 2002;216:355-358 (Pubitemid 44858345)
24. Elibol O, Ozkan B, Hekimhan PK, Caolar Y. Efficacy of skin cooling and EMLA cream application for pain relief of periocular botulinum toxin injection. Ophthal Plast Reconstr Surg 2007;23: 130-133 (Pubitemid 46596604)
25. Linder JS, Edmonson BC, Laquis SJ, et al. Skin cooling before periocular botulinum toxin A injection. Ophthal Plast Reconstr Surg 2002;18:441-442 (Pubitemid 35356226)